AKEBIA THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $3.24M, a 110.12% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.54M.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $64.91M, a 246.36% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $1.66M.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $66.45M, a 56.37% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $42.49M, a 533.50% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $6.71M, a 5.81% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $7.12M, a 91.93% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $3.24M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $66.45M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $1.54M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $64.91M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $42.49M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.66M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $18.74M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $6.71M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $7.12M 10-K · filed 2024-03-14 | |
| 2022-03-31 | $7.18M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $88.20M 10-K/A · filed 2023-08-28 | |
| 2021-09-30 | $16.09M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $37.27M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $29.50M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $209.52M 10-K/A · filed 2023-08-28 | |
| 2020-06-30 | $142.38M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $56.58M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $25.79M 10-K · filed 2022-03-01 | |
| 2019-06-30 | $9.04M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $95.45M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $36.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $95.42M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $114.58M 10-K · filed 2020-03-12 | |
| 2016-12-31 | $66.62M 10-K · filed 2019-03-26 | |
| 2015-12-31 | $82.75M 10-K · filed 2018-03-12 | |
| 2014-12-31 | $114.95M 10-K · filed 2017-03-06 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |